hydroxyapatite coating amorphous phase crystallinity iso

Plasma-sprayed hydroxyapatite coatings on titanium and cobalt-chromium implants contain crystalline calcium phosphate phases plus an amorphous component. This amorphous fraction dissolves faster than crystalline hydroxyapatite, so its quantification—expressed as crystallinity or amorphous-phase content—is a release-relevant characteristic. ISO 13779 specifies X-ray diffraction as the reference method, supported by infrared spectroscopy and related test items.

Hydroxyapatite

coating amorphous phase crystallinity ISO testing

Plasma-sprayed hydroxyapatite coatings solidify at extreme cooling rates. A fraction of the melt does not crystallize. This amorphous calcium phosphate, plus secondary crystalline phases such as tricalcium phosphate, tetracalcium phosphate and calcium oxide, determines how the coating behaves after implantation. ISO 13779 addresses this by specifying composition, crystallinity and dissolution requirements for hydroxyapatite coatings on medical implants. X-ray diffraction is the designated reference technique for phase identification and crystallinity determination. The concept is simple in principle. The diffraction pattern of the coating is compared with that of a fully crystalline reference. The ratio of crystalline scattering to total scattering yields a crystallinity index. In practice, the measurement is sensitive to specimen geometry, substrate correction and preferred orientation. Standardized sample preparation and instrument conditions are therefore required for comparable results between laboratories.

Sample

preparation and coating specimen handling

Specimen handling begins with a recognition: the coating is a thin, fragile layer bonded to a metallic substrate, typically titanium alloy. Whenever possible, diffraction and infrared measurements are performed directly on the coated surface. The specimen is cut or sectioned to fit the sample holder without bending, since bending would crack or spall the coating. Cutting must use low-force abrasive methods with coolant, followed by solvent degreasing to remove machining residues. Loose powder from the same production batch may also be characterized for feedstock comparison. However, coating crystallinity after spraying is always lower than powder crystallinity because of melt quenching. Cross-sectioned mounts are used only when coating thickness or interface structure must be examined. Etching is avoided because it alters phase distribution. Documentation of specimen identity, coated area and surface condition precedes any measurement. These precautions parallel general practice in coating testing programs. They also apply in specialized areas such as conformal coating testing, where surface condition directly governs analytical validity.

Crystallinity

determination by XRD and FTIR

X-ray diffraction is the primary method. The coating surface is scanned over the 2θ range covering the principal hydroxyapatite reflections. Crystallinity is calculated either by intensity-ratio methods—comparing selected peak heights or integrated areas against an amorphous baseline—or by full-pattern refinement. Refinement models amorphous and crystalline contributions simultaneously. Phase identification is performed against reference patterns to detect tricalcium phosphate and other secondary phases. Fourier-transform infrared spectroscopy offers a complementary approach. The phosphate vibrational bands broaden and structural OH bands weaken as amorphous content increases. Band-splitting indices in the 500–650 cm⁻¹ and 900–1200 cm⁻¹ regions can therefore be calibrated against XRD values. FTIR also detects carbonate substitution and contamination such as beta-phase residues. Laboratories routinely pair the two techniques, using XRD for reporting and FTIR for rapid verification. This resembles how Analytical Tools to Aid in Coating Formulation Development combine orthogonal measurements to cross-check composition.

ISO 13779 and ASTM F1185 test items

ISO 13779 defines hydroxyapatite as a calcium phosphate with a defined Ca/P ratio. It sets out crystallinity determination by XRD as part of its coating characterization suite, alongside chemical composition, trace impurity analysis, coating thickness, adhesion strength and dissolution behavior. The standard requires that secondary crystalline phases be reported. It also places limits on the amorphous-plus-secondary fraction, since excessive amorphous content accelerates early coating loss. ASTM F1185 specifies the compositional requirements of hydroxyapatite for surgical implants. These include permitted levels of trace elements and impurity phases. The standard is frequently invoked together with ISO 13779 in submission dossiers. A complete test item list for a coated implant therefore includes crystallinity and amorphous content, phase purity, Ca/P ratio by ICP-OES or XRF, heavy metal screening, thickness, tensile adhesion per ASTM F1147 and dissolution testing. Item selection depends on the regulatory pathway and the design claims declared by the manufacturer.

Sensitivity,

repeatability and precision metrics

Thin coatings challenge diffraction sensitivity because the coating mass is small relative to the substrate. Substrate reflections can intrude at low angles. Grazing-incidence geometry and adequate counting times improve the signal-to-background ratio. Amorphous content above roughly the ten percent level is quantifiable under routine conditions. Repeatability is assessed by replicate scans of the same specimen and by re-mounting, which separates instrumental variance from placement effects. Between-operator and between-day studies establish intermediate precision. Comparison against a fully crystalline hydroxyapatite reference material verifies the calibration of the crystallinity scale. Results are reported with the calculation method stated, since ratio methods and full-pattern methods give different numerical crystallinity for the same specimen. Precision statements in the test report should identify scan range, step size, counting time and the crystallinity model applied. This discipline mirrors practices in Anti-corrosion Coating Testing and anti-static coating testing, where measurement conditions must be fixed before results from different batches can be compared.

Application

to orthopedic and dental implants

For hip stems, dental roots, spinal cages and trauma plates, crystallinity data feed directly into design control and biological performance prediction. A coating with higher amorphous content dissolves faster. It releases calcium and phosphate ions that can stimulate early bone apposition. However, excessive amorphous content risks coating resorption before bone ongrowth is established. Manufacturers therefore define an internal crystallinity window supported by batch XRD data, dissolution testing and adhesion results. Reviewers examine the consistency of these values across production lots. Crystallinity also serves as a process-control indicator for plasma-spray parameters. Changes in plasma power, standoff distance or powder feed rate shift the amorphous fraction measurably. Periodic XRD checks therefore detect process drift before dimensional or adhesion failures appear. During design changes—new substrates, revised spray cycles or alternative powder suppliers—crystallinity verification closes the loop. The resulting report supports regulatory submissions, supplier qualification and routine release testing of implant batches.